JP2011519867A5 - - Google Patents

Download PDF

Info

Publication number
JP2011519867A5
JP2011519867A5 JP2011507701A JP2011507701A JP2011519867A5 JP 2011519867 A5 JP2011519867 A5 JP 2011519867A5 JP 2011507701 A JP2011507701 A JP 2011507701A JP 2011507701 A JP2011507701 A JP 2011507701A JP 2011519867 A5 JP2011519867 A5 JP 2011519867A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
fatty acid
item
salt
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011507701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519867A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/042627 external-priority patent/WO2009135190A2/en
Publication of JP2011519867A publication Critical patent/JP2011519867A/ja
Publication of JP2011519867A5 publication Critical patent/JP2011519867A5/ja
Pending legal-status Critical Current

Links

JP2011507701A 2008-05-01 2009-05-01 治療用リン酸カルシウム粒子、ならびにその作製および使用方法 Pending JP2011519867A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4962708P 2008-05-01 2008-05-01
US61/049,627 2008-05-01
PCT/US2009/042627 WO2009135190A2 (en) 2008-05-01 2009-05-01 Therapeutic calcium phosphate particles and methods of making and using same

Publications (2)

Publication Number Publication Date
JP2011519867A JP2011519867A (ja) 2011-07-14
JP2011519867A5 true JP2011519867A5 (enExample) 2012-06-21

Family

ID=41137579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507701A Pending JP2011519867A (ja) 2008-05-01 2009-05-01 治療用リン酸カルシウム粒子、ならびにその作製および使用方法

Country Status (5)

Country Link
US (1) US20120128767A1 (enExample)
EP (1) EP2285361A2 (enExample)
JP (1) JP2011519867A (enExample)
CN (1) CN102014880A (enExample)
WO (1) WO2009135190A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011084618A2 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
WO2012145801A1 (en) * 2011-04-29 2012-11-01 Jagat Rakesh Kanwar Nanoparticle
WO2014064710A1 (en) 2012-10-22 2014-05-01 Department Of Biotechnology A process for the prepartion of non-viral vector for delivery of nucleic acids by mucosal route
CN103073645B (zh) * 2012-12-31 2014-06-18 浙江大学 一种生物矿化的胰岛素蛋白纳米颗粒及其制备方法和应用
GB201319548D0 (en) * 2013-11-05 2013-12-18 Medical Res Council Amorphous magnesium-substituted calcium phosphate compositions and their uses
EP3142645A4 (en) 2014-05-15 2017-12-27 Rani Therapeutics, LLC Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
EP3220967B8 (en) * 2014-11-17 2019-11-20 NanotecMARIN GmbH Morphogenetically active amorphous calcium polyphosphate nanoparticles for therapeutic applications
JP7306718B2 (ja) * 2017-03-13 2023-07-11 エスディージー インコーポレイテッド 向上した安定性を有する脂質ベースのナノ粒子
IL298362A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Coronavirus antigen compositions and their uses
JP2024501288A (ja) 2020-12-23 2024-01-11 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー 修飾tremの組成物及びその使用
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
EP4271818B1 (en) 2021-09-17 2024-07-31 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing circular polyribonucleotides
TW202322826A (zh) 2021-10-18 2023-06-16 美商旗艦先鋒創新有限責任公司 用於純化多核糖核苷酸之組成物及方法
JP2025511756A (ja) 2022-04-08 2025-04-16 フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー ワクチン及び関連する方法
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
EP4544043A1 (en) 2022-06-22 2025-04-30 Flagship Pioneering Innovations VI, LLC Compositions of modified trems and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
AU2023372397A1 (en) 2022-10-31 2025-05-08 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
EP4615465A1 (en) 2022-11-08 2025-09-17 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing circular polyribonucleotides
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任(Vii)公司 用於將治療劑遞送至骨之組成物和方法
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024151673A2 (en) 2023-01-09 2024-07-18 President And Fellows Of Harvard College Recombinant nucleic acid molecules and their use in wound healing
TW202438515A (zh) 2023-02-06 2024-10-01 美商旗艦先鋒創新有限責任(Vii)公司 免疫調節組合物及相關方法
US20240293318A1 (en) 2023-02-13 2024-09-05 Flagship Pioneering Innovations Vii, Llc Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions
IL322201A (en) 2023-02-17 2025-09-01 Flagship Pioneering Innovations Vii Llc DNA structures containing modified uracil
AU2024252590A1 (en) 2023-04-12 2025-10-23 Flagship Pioneering Innovations Vi, Llc Trems for use in correction of missense mutations
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2025024486A2 (en) 2023-07-25 2025-01-30 Flagship Pioneering Innovations Vii, Llc Cas endonucleases and related methods
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025096807A2 (en) 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms
TW202535835A (zh) 2023-11-14 2025-09-16 美商旗艦先鋒創新有限責任(Vii)公司 可電離類脂質組成物及其治療用途
WO2025194019A1 (en) 2024-03-14 2025-09-18 Flagship Pioneering Innovations Vii, Llc Methods for treating liver fibrosis and non-alcoholic fatty liver disease
WO2025245188A2 (en) 2024-05-21 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods of treating liver steatosis and non-alcoholic fatty liver disease
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
CN118370728B (zh) * 2024-06-24 2024-11-08 山东则正医药技术有限公司 一种glp-1ra载药纳米颗粒和制剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460830A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Biochemically active agents for chemical catalysis and cell receptor activation
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5462751A (en) 1990-06-22 1995-10-31 The Regeants Of The University Of California Biological and pharmaceutical agents having a nanomeric biodegradable core
US5219577A (en) 1990-06-22 1993-06-15 The Regents Of The University Of California Biologically active composition having a nanocrystalline core
MXPA01007895A (es) 1999-02-03 2003-07-21 Biosante Pharmaceuticals Inc Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos.
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US20070004623A1 (en) * 2003-10-27 2007-01-04 Innodia Inc. Use of hydroxylated amino acids for treating diabetes
ATE470433T1 (de) * 2004-02-13 2010-06-15 Nod Pharmaceuticals Inc Partikel mit kern aus calciumphosphat- nanopartikeln, biomolekül und gallensäure, herstellungsverfahren und therapeutische verwendung

Similar Documents

Publication Publication Date Title
JP2011519867A5 (enExample)
Rai et al. Novel drug delivery system: an immense hope for diabetics
Cai et al. Long-acting preparations of exenatide
Wong Design of oral insulin delivery systems
Chen et al. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules
Chalasani et al. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin
CN1993113B (zh) 包含磷酸钙纳米颗粒核心,生物分子和胆汁酸的颗粒,其生产方法,其治疗用途
Nguyen et al. The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo
CN106974888B (zh) 药物组合物和相关的给药方法
Song et al. Nanolayer encapsulation of insulin-chitosan complexes improves efficiency of oral insulin delivery
US20110189299A1 (en) Pharmaceutical composition containing surface-coated microparticles
Hwang et al. Advances in oral macromolecular drug delivery
EP1466610A1 (en) Medicinal compositions for nasal absorption
JP5491119B2 (ja) 薬物含有微粒子を含む医薬組成物およびその製造方法
Babu et al. Developments in polymeric devices for oral insulin delivery
Peng et al. Challenges and opportunities in delivering oral peptides and proteins
JP2008505919A5 (enExample)
JP2013525351A (ja) ナノ粒子の医薬組成物
US20180271792A1 (en) Oral delivery of physiologically active substances
Verma et al. Emerging trends in noninvasive insulin delivery
WO2007093999A1 (en) A gastro-retentive system for the delivery of macromolecules
Chin et al. Insight of current technologies for oral delivery of proteins and peptides
Fuhrmann et al. Recent advances in oral delivery of macromolecular drugs and benefits of polymer conjugation
CN110612114A (zh) 具有增强的稳定性的基于脂质的纳米颗粒
Li et al. Advances in subcutaneous delivery systems of biomacromolecular agents for diabetes treatment